Two pathways differentially linking tau depositions, oxidative stress, and neuronal loss to apathetic phenotypes in progressive supranuclear palsy.

Humans tau Proteins / metabolism Supranuclear Palsy, Progressive / diagnostic imaging Apathy Brain / pathology Positron-Emission Tomography / methods Oxidative Stress
Apathy Oxidative stress Positron-emission tomography Progressive supranuclear palsy Tau

Journal

Journal of the neurological sciences
ISSN: 1878-5883
Titre abrégé: J Neurol Sci
Pays: Netherlands
ID NLM: 0375403

Informations de publication

Date de publication:
15 01 2023
Historique:
received: 12 10 2022
revised: 21 11 2022
accepted: 26 11 2022
pubmed: 7 12 2022
medline: 24 1 2023
entrez: 6 12 2022
Statut: ppublish

Résumé

Patients with progressive supranuclear palsy (PSP) frequently exhibit apathy but the neuropathological processes leading to this phenotype remain elusive. We aimed to examine the involvement of tau protein depositions, oxidative stress (OS), and neuronal loss in the apathetic manifestation of PSP. Twenty patients with PSP and twenty-three healthy controls were enrolled. Tau depositions and brain volumes were evaluated via positron-emission tomography (PET) using a specific probe,

Identifiants

DOI: 10.1016/j.jns.2022.120514 PMID: 36473346
pubmed: 36473346
pii: S0022-510X(22)00376-8
doi: 10.1016/j.jns.2022.120514
pii:
doi:

Substances chimiques

tau Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

120514

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest H.Sd., M.-R.Z., T.S., and M.H. hold patents on compounds related to the present report (JP 5422782/EP 12 884 742.3/CA2894994/HK1208672). All other authors report no biomedical financial interests or potential conflicts of interest.

Auteurs

Kiwamu Matsuoka (K)

Department of Functional Brain Imaging, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan; Department of Psychiatry, Nara Medical University, Kashihara, Japan.

Yuhei Takado (Y)

Department of Functional Brain Imaging, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan. Electronic address: takado.yuhei@qst.go.jp.

Kenji Tagai (K)

Department of Functional Brain Imaging, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.

Manabu Kubota (M)

Department of Functional Brain Imaging, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan; Department of Psychiatry, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Yasunori Sano (Y)

Department of Functional Brain Imaging, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.

Keisuke Takahata (K)

Department of Functional Brain Imaging, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.

Maiko Ono (M)

Department of Functional Brain Imaging, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.

Chie Seki (C)

Department of Functional Brain Imaging, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.

Hideki Matsumoto (H)

Department of Functional Brain Imaging, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan; Department of Oral and Maxillofacial Radiology, Tokyo Dental College, Tokyo, Japan.

Hironobu Endo (H)

Department of Functional Brain Imaging, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.

Hitoshi Shinotoh (H)

Department of Functional Brain Imaging, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan; Neurology Clinic, Chiba, Chiba, Japan.

Yasuka Sahara (Y)

Department of Molecular Imaging and Theranostics, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.

Takayuki Obata (T)

Department of Molecular Imaging and Theranostics, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.

Jamie Near (J)

Douglas Mental Health University Institute and Department of Psychiatry, McGill University, Quebec City, Canada.

Kazunori Kawamura (K)

Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.

Ming-Rong Zhang (MR)

Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.

Tetsuya Suhara (T)

Department of Functional Brain Imaging, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.

Hitoshi Shimada (H)

Department of Functional Brain Imaging, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan; Department of Functional Neurology & Neurosurgery, Center for Integrated Human Brain Science, Brain Research Institute, Niigata University, Niigata, Japan. Electronic address: shimada.hitoshi@bri.niigata-u.ac.jp.

Makoto Higuchi (M)

Department of Functional Brain Imaging, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Two pathways differentially linking tau...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines de tissu nerveux › Protéines associées aux microtubules › Protéines tau › Two pathways differentially linking tau...
questionsmedicales.fr › États, signes et symptômes pathologiques › Signes et symptômes › Manifestations neurologiques › Paralysie › Ophtalmoplégie › Paralysie supranucléaire progressive › Two pathways differentially linking tau...
questionsmedicales.fr › Comportement et mécanismes comportementaux › Émotions › Apathie › Two pathways differentially linking tau...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Two pathways differentially linking tau...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Two pathways differentially linking tau...
questionsmedicales.fr › Phénomènes physiologiques › Stress physiologique › Stress oxydatif › Two pathways differentially linking tau...